Equipping Biopharma’s Legal Leaders to Lead with Clarity, Drive AI-Enabled Operational Efficiency & Thrive Amid Relentless Change
The 7th In-House Impact: Biopharma Summit arrives at a time when General Counsels across biopharma are facing a uniquely demanding 2026. FDA expectations remain unsettled, pricing reform continues to evolve, geopolitical tensions are shifting global partnerships and supply chains, and AI is reshaping how legal teams operate. In this environment, GCs must deliver sharper strategic judgment, stronger operational efficiency and clearer enterprise leadership.
This is the only US forum built exclusively for senior in-house legal leaders across early, growth and commercial stage biopharma organizations. Featuring speakers from companies including Olema Oncology, Caribou Biosciences, Enveda Biosciences, Takeda Oncology, Legend Biotech, Boundless Bio and Sionna Therapeutics, the summit brings together the legal decision makers shaping how scientific assets translate into enterprise value.
Across two focused days, you will compare approaches to navigating FDA volatility, preparing for pricing reform, designing responsible AI governance, safeguarding IP and trade secrets, strengthening compliance maturity, anticipating crossborder risk and improving deal readiness across partnerships, M&A and IPO preparation.
Free to attend for inhouse counsel, this is the only place where biopharma GCs and CLOs benchmark with true peers, share candid insight and return with practical strategies they can implement immediately.
Attending Companies Include